Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor

Aug 13, 2020

|

NEW YORK – Ann Arbor, Michigan-based Strata Oncology on Thursday announced that it has entered into a partnership with Mirati Therapeutics to identify and enroll patients with KRAS GI12C mutations into Mirati's Phase I/II study of MRTX849 as a treatment for patients with advanced solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Novel Artificial Intelligence (AI)-based Technology to Improve Oncology Clinical Trial Fulfillment

Circulating Protein Biomarkers are a Promising Avenue for Predicting Patient Response to Cancer Immunotherapies

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct

15

Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct

27

Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Menu

Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor

To read the full story....

Breaking News

Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer

Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Relay Therapeutics Uses Protein Motion Simulation to Develop Highly Selective Precision Cancer Drugs

Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Multi-Biomarker Strategies Show Promise in Improving Immunotherapy Response Prediction

BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer

Sponsorships